

Constituents of the Stem of *Angelica gigas* with Rat Lens Aldose Reductase Inhibitory Activity

Hyun Young Park¹, Soon Bae Kwon², Nam Kee Heo², Wan Joo Chun³,
Myong Jo Kim⁴, and Yong Soo Kwon^{1*}

¹College of Pharmacy, Kangwon National University, Chuncheon 200-701, Republic of Korea

²Speciality Crops Experimental Stations, GARES, Chuncheon 200-150, Republic of Korea

³College of Medicine, Kangwon National University, Chuncheon 200-701, Republic of Korea

⁴Oriental Bio-Herb Research Institute, Kangwon National University, Chuncheon 200-701, Republic of Korea

Received November 19, 2010; Accepted January 6, 2011

Eleven compounds were isolated from the stem of *Angelica gigas*. On the basis of spectral data, these compounds were identified as isoimperatorin (1), 7-methoxy-5-prenyloxycoumarin (2), imperatorin (3), decursin (4), bergapten (5), psoralen (6), xanthotoxin (7), *p*-hydroxyphenethyl *trans*-ferulate (8), visamminol (9), scopoletin (10), and 3'-hydroxyxanthyletin (11). All isolates were evaluated *in vitro* for their inhibitory activities on the rat lens aldose reductase. Tested compounds (1-11) exhibited inhibitory activities against rat lens aldose reductase with IC₅₀ values ranging from 2.59 to 191.91 μM.

Key words: *Angelica gigas*, ¹³C-nuclear magnetic resonance, chromone, coumarins, diabetic complications, 3'-hydroxyxanthyletin, inhibitory activity, rat lens aldose reductase, stem

Acceleration of the polyol pathway [Yabe-Nishimura, 1998], nonenzymatic glycation [Friedman, 1999], activation of protein kinase C [Koya and King, 1998] and oxidative stress [Baynes and Thorpe, 1999] are considered as the prime mechanisms underlying complications such as cataracts, retinopathy, and nephropathy of diabetes mellitus.

Aldose reductase (AR), the key enzyme in the polyol pathway, has been reported to play an important role in the pathogenesis of diabetic complications [Santiago, 1993; Feldman *et al.*, 1997]. AR inhibitors are considered as preventive agents used for diabetic complications [Boel *et al.*, 1995]. Thus, many studies have reported various natural compounds from plant sources, which act as AR inhibitors [Shimizu *et al.*, 1984; Ueda *et al.*, 2004; Manzanaro *et al.*, 2006; Jung *et al.*, 2008; Endo *et al.*, 2009].

Although *A. gigas* has been reported to be a good source of coumarins, which exhibit AR inhibitory activity [Ryu and Yook, 1967; Ryu *et al.*, 1990; Okada *et al.*, 1995; Kang *et al.*, 2001; Lee *et al.*, 2002; Kang and Kim, 2007], the chemical composition and biological activities

of *A. gigas* have not been fully elucidated [Kim *et al.*, 2009]. Therefore, the present study examined the constituents of the stem of *A. gigas* and their biological activity, with focus on isolation, structure elucidation, and AR inhibitory activity.

Materials and Methods

General procedures. Melting point was determined on a Fisher Johns melting point apparatus (Philadelphia, PA). UV/Vis spectra were measured on a V-530 spectrophotometer (JASCO, Tokyo, Japan). Optical rotation was measured on a DIP 1000 Digital Polarimeter (JASCO). Infrared (IR) spectrum was measured on a Fourier transform infrared (FTIR)-4200 (JASCO). MS (Mass spectroscopy) spectrum was measured on a Autospec M363 (Micromass, Manchester, England). Nuclear magnetic resonance (NMR) spectrum was recorded on DPX 400 and AVANCE 600 (Bruker, Rheinstetten, Germany). The chemical shifts were represented as parts per million (ppm) referenced to the residual solvent signal. Column chromatography was carried out using Kieselgel 60, 400-230 mesh (Merck, Darmstadt, Germany) and YMC gel octadecyl silyl-silica gel (ODS)-A, 150 mm (YMC, Kyoto, Japan). Thin-layer chromatography (TLC) was performed on glass backed Kieselgel 60 F₂₅₄ and RP F_{254s}

*Corresponding author

Phone: +82-33-250-6921; Fax: +82-33-255-7865

E-mail: yskwon@kangwon.ac.kr

plates (Merck).

Plant material. *A. gigas* was collected from Tae-Baek (September, 2009), Korea. A voucher specimen (KNUH-S-0903) was deposited in the herbarium of the College of Pharmacy, Kangwon National University, Korea.

Extraction and isolation. The dried stem of *A. gigas* (1.8 kg) was refluxed with hot methanol (MeOH) for 3 h, three times. The MeOH extract (71 g) was suspended in water and then successively partitioned with *n*-hexane, CHCl₃, and *n*-BuOH. Each soluble fraction was evaporated *in vacuo* to yield the residues of *n*-hexane (7 g), CHCl₃ (50 g), and *n*-BuOH (10 g) extracts. Among these extracts, CHCl₃ extracts exhibited 85% inhibition on AR (10 µg/mL). The CHCl₃ soluble fraction (50 g) was column chromatographed on a silica gel (1 kg, 10×50 cm) using isocratic elution with benzene:ethyl acetate (EtOAc) (4:1 to 1:2, gradient), to afford ten fractions (Fr. 1-Fr. 10). Fr. 2 was re-chromatographed on silica gel (100 g, 2.5×50 cm) by elution with hexane:EtOAc (9:1) to afford nine sub-fractions (Fr. 1-1–Fr. 1-9). Fr. 2-4 was re-chromatographed on silica gel (30 g, 3×20 cm) by elution with benzene:EtOAc (39:1) to give compound **1** (20 mg). Fr. 2-5 was re-chromatographed on a silica gel (30 g, 3×20 cm) by elution with benzene:EtOAc (39:1) to give compound **2** (4 mg). Fr. 2-8 was re-chromatographed on silica gel (30 g, 3×20 cm) by elution with benzene:EtOAc (39:1) to afford four sub-fractions (Fr. 2-8-1–2-8-4). Fr. 2-8-3 was re-chromatographed on an ODS column (30 g, 3×20 cm) and silica gel column (30 g, 3×20 cm) by elution with MeOH:H₂O (70:30) and benzene:EtOAc (39:1) to give compound **3** (3 mg). Fr. 3 was re-chromatographed on ODS column (300 g, 10×50 cm) by elution with MeOH:H₂O (80:20) to afford three sub-fractions (Fr. 3-1–3-3). Compound **4** (5 g) was isolated through ODS column (100 g, 2.5×50 cm) of Fr. 3-2 with an acetonitril:H₂O (70:30). Fr. 3-1 was re-chromatographed on ODS column (30 g, 3×20 cm) by elution with MeOH:H₂O (50:50) to afford seven sub-fractions (Fr. 3-1-1–3-1-7) from which compound **5** (230 mg) was obtained. Compounds **6** (10 mg) and **7** (40 mg) were isolated through additional silica gel column chromatography (30 g, 3×20 cm) of Fr. 3-1-4 with benzene:EtOAc (49:1). Fr. 4 was re-chromatographed on silica gel (100 g, 2.5×50 cm) by elution with *n*-hexane:EtOAc (2:1) to afford five sub-fractions (Fr. 4-1–Fr. 4-5). Fr. 4-4 was re-chromatographed silica gel column (80 g, 2.5×50 cm) and ODS column (30 g, 3×20 cm) by elution with *n*-hexane:EtOAc (2:1) and benzene:EtOAc (9:1) and MeOH:H₂O (70:30) to give compound **8** (250 mg). Fr. 6 was re-chromatographed on a silica gel (100 g, 2.5×50 cm) by elution with chloroform (CHCl₃):MeOH (49:1) and divided into four sub-fractions (Fr. 6-1–Fr. 6-4). Fr. 6-2 was re-chromatographed on an ODS

column (60 g, 2.5×50 cm) by elution with acetonitril:MeOH (50:50) to afford eight sub-fractions (Fr. 6-2-1–6-2-8). Fr. 6-2-4 was re-chromatographed on a silica gel (30 g, 3×20 cm) by elution with CHCl₃:MeOH (39:1) to give compound **9** (25 mg). Fr. 7 was re-chromatographed on a silica gel (100 g, 2.5×50 cm) by elution with benzene:EtOAc (4:1) to afford three sub-fractions (Fr. 7-1–7-3). Fr. 7-2 was re-chromatographed on an ODS column (30 g, 3×20 cm) by elution with MeOH:H₂O (50:50) to give compounds **10** (7 mg), and **11** (45 mg).

Compound **11**: UV (MeOH) λ_{max} 206, 248, 295, 333; ¹H-NMR (600 MHz, acetone-*d*₆) and ¹³C-NMR (125 MHz, acetone-*d*₆), see Table 1 for spectral data; EI-MS *m/z*: 244 [M]⁺

Assay for AR inhibition activity. Rat Lens were removed from the eyes of 8 weeks old Sprague-Dawley rats (Dae Han Bio Link Co., Umsung, Korea) each weighing 130-150 g and homogenized in 100 mM sodium phosphate buffer (pH 6.2). The homogenate was centrifuged at 10,000 rpm at 4°C for 20 min to obtained supernatant as the crude rat lens aldose reductase (RLAR). Reaction mixture contained 0.15 mM nicotine amide dinucleotide phosphate reduced form (NADPH), 10 mM DL-glyceraldehyde, 100 µL RLAR, and 10 µL test sample solution or dimethylsulfoxide (DMSO) to a total volume of 1 mL of 100 mM sodium phosphate buffer (pH 6.2). The reaction mixtures were pre-incubated at 25°C for 3 min, and the reaction was started by addition of the enzyme. Decrease in absorbance was measured at 340 nm using a JASCO V-530 spectrophotometer. The inhibitory activity (%) was estimated as follows: $[1 - (\Delta A \text{ sample/min} - \Delta A \text{ blank/min}) / (\Delta A \text{ control/min} - \Delta A \text{ blank/min})] \times 100$. ΔA sample/min showed a decrease in absorbance for 1 min with a sample, ΔA blank/min with DMSO and water instead of sample and substrate, and ΔA control/min with DMSO instead of sample and substrate.

Result and Discussion

The structures of **1-10** were identified as isoimperatorin (**1**) [Wei and Ito, 2006], 7-methoxy-5-prenyloxycoumarin (**2**) [Kang *et al.*, 2001], imperatorin (**3**) [Wei and Ito, 2006], decursin (**4**) [Lee *et al.*, 2002], bergapten (**5**) [Bergendorff *et al.*, 1997], psoralen (**6**) [Masuda *et al.*, 1998], xanthotoxin (**7**) [Sasaki *et al.*, 1982], Hydroxyphenethyl *trans*-ferulate (**8**) [Nakata *et al.*, 1982], visamminol (**9**) [Baba *et al.*, 1981], and scopoletin (**10**) [Gözler *et al.*, 1984] by comparison of their spectral data with those of literature values (Fig. 1). Isoimperatorin (**1**) and imperatorin (**3**) have been reported to exhibit β -secretase inhibition activity [Marumoto and Miyazawa, 2010], antiproliferative effects [Kim *et al.*, 2007], and




Fig. 1. Structures of 1-11 isolated from the stem of *A. gigas*.

acetylcholinesterase inhibition activity [Kim *et al.*, 2002]. 7-Methoxy-5-prenyloxycoumarin (**2**) was reported to possess neuroprotective effect [Epifano *et al.*, 2008] and an acetylcholinesterase inhibition effect [Kang *et al.*, 2001], and decursin (**4**) was shown to exhibit acetylcholinesterase inhibitory effects [Kang *et al.*, 2001] and anticancer properties [Kim *et al.*, 2010]. Bergapten (**5**), psoralen (**6**), and xanthotoxin (**7**) have been reported to

possess topoisomerase I inhibitory activity [Diwan and Malpathak, 2009]. *p*-Hydroxyphenethyl *trans*-ferulate (**8**) was shown to exhibit cancer preventive activity [Xiao and Parkin, 2006] and serotonergic activity [Deng *et al.*, 2006]. Visaminol (**9**) has been reported to possess antiplatelet aggregation activity [Chen *et al.*, 1996]. Scopoletin (**10**) was demonstrated to exhibit adipocyte differentiation inhibitory activity [Shin *et al.*, 2010], anti-

Table 1. ¹H- and ¹³C-NMR data for **11** (in acetone-*d*₆)

Position	δ_{H} (<i>J</i> =Hz)		δ_{C}	
	11	3'-hydroxyxanthyletin ^a	11	3'-hydroxyxanthyletin ^a
2			160.05	‡
3	6.36 (d, 9.6)	6.38 (d, 9.6)	114.07	114.8
4	8.06 (d, 9.6)	7.79 (d, 9.6)	144.40	144.3
5	7.84 (s)	7.61 (s)	119.96	100.2
6			126.02	‡
7			156.18	‡
8	7.46 (s)	7.45 (s)	98.86	100.0
9			151.88	‡
10			115.39	‡
2'			68.19	71.0
3'			166.93	164.0
4'	6.78 (s)	6.64 (s)	99.85	119.7
2×Me-2'	1.63 (s)	1.70 (s)	28.35	28.9

The assignments were based on HMBC, HSQC, and COSY experiments.

‡Not observed

^aData from Satyajit *et al.*, 1995.

- and Ko FN (1996) Coumarins and antiplatelet aggregation constituents from formosan *Peucedanum japonicum*. *Phytochemistry* **41**, 525-530.
- Deng S, Chen SN, Yao P, Nikolic D, van Breemen RB, Bolton JL, Fong HH, Farnsworth NR, and Pauli GF (2006) Serotonergic activity-guided phytochemical investigation of the roots of *Angelica sinensis*. *J Nat Prod* **69**, 536-541.
- Diwan R and Malpathak N (2009) Furocoumarins: novel topoisomerase I inhibitors from *Ruta graveolens* L. *Bioorg Med Chem* **17**, 7052-7055.
- Endo S, Toshiyuki M, Mamiya H, Ohta C, Soda M, Kitade Y, Tajima K, Hai-Tao Z, El-Kabbani O, and Hara A (2009) Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. *Arch Biochem Biophys* **487**, 1-9.
- Epifano F, Molinaro G, Genovese S, Ngomba RT, Nicoletti F, and Curini M (2008) Neuroprotective effect of prenyloxycoumarins from edible vegetables. *Nerisci Lett* **443**, 57-60.
- Feldman EL, Stevens MJ, and Greene DA (1997) Pathogenesis of diabetic neuropathy. *Clin Neurosci* **4**, 365-370.
- Friedman AE (1999) Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. *Diabetes Care* **22** Sup 2, B65-B71.
- Gözler T, Gözler B, Patra A, Leet EJ, Freyer JA, and Samma M (1984) Konyanin: a new lignin from *Haplophyllum vulcanicum*. *Tetrahedron* **40**, 1145-1150.
- Jung HA, Yoon NY, Bae HJ, Min BS, and Choi JS (2008) Inhibitory activities of the alkaloids from *Coptidis rhizoma* against aldose reductase. *Arch Pharm Res* **31**, 1405-1412.
- Kang SY and Kim YC (2007) Neuroprotective coumarins from the roots of *Angelica gigas*: structure-activity relationships. *Arch Pharm Res* **30**, 1368-1373.
- Kang SY, Lee KY, Sung SH, Park MJ, and Kim YC (2001) Coumarins isolated from *Angelica gigas* inhibit acetylcholinesterase: structure-activity relationships. *J Nat Prod* **64**, 683-685.
- Kim DK, Lim JP, Yang JH, Eom DO, Eun JS, and Leem KH (2002) Acetylcholinesterase inhibitors from the roots of *Angelica dahurica*. *Arch Pharm Res* **25**, 856-859.
- Kim GS, Park CG, Jeong TS, Cha SW, Baek NI, and Song KS (2009) ACAT (Acyl-CoA : cholesterol acyltransferase) inhibitory effect and quantification of pyranocoumarin in different parts of *Angelica gigas* Naki. *J Appl Biol Chem* **52**, 187-194.
- Kim WJ, Lee SJ, Choi YD, and Moon SK (2010) Decursin inhibits growth of human bladder and colon cancer cell via apoptosis, G1-phase cell cycle arrest and extracellular signal-regulated kinase activation. *Int J Mol Med* **25**, 635-641.
- Kim YK, Kim YS, and Ryu SY (2007) Antiproliferative effect of furanocoumarins from the root of *Angelica dahurica* on cultured human tumor cell lines. *Phytother Res* **21**, 288-290.
- Koya D and King LG (1998) Perspectives in diabetes: protein kinase C activation and the development of diabetic complications. *Diabetes* **47**, 859-866.
- Lee SH, Kang SS, and Shin KH (2002) Coumarins and a pyrimidine from *Angelica gigas* roots. *Nat Prod Sci* **8**, 58-61.
- Manzanaro S, Salva J, and de la Fuente JA (2006) Phenolic marine natural products as aldose reductase inhibitors. *J Nat Prod* **69**, 1485-1487.
- Marumoto S and Miyazawa M (2010) β -Secretase inhibitory effect of furanocoumarins from the root of *Angelica dahurica*. *Phytother Res* **24**, 510-513.
- Masuda T, Takasugi M, and Anetai M (1998) Psoralen and other linear furanocoumarins as phytoalexins in *Glehnia littoralis*. *Phytochemistry* **47**, 13-16.
- Mishra N, Oraon A, Dev A, Jayaprakash V, Basu A, Pattnaik KA, Tripathi NS, Akahtar M, Ahmad S, Swaroop S, and Basu M (2010) Anticonvulsant activity of *Benkara malabarica* (Linn.) root extract: *in vitro* and *in vivo* investigation. *J Ethnopharmacol* **128**, 533-536.
- Nakata H, Sahida Y, and Shimamura H (1982) A New phenolic compound from *Heracleum lanata* MICH. var. *nippinicum* HARA II. *Chem Pharm Bull* **30**, 4554-4556.
- Okada Y, Miyauchi N, Suzuki K, Kobayashi T, Tsutsui C, Mayuzumi K, Nishibe S, and Okuyama T (1995) Search for naturally occurring substances to prevent the complications of diabetes. II. Inhibitory effect of coumarin and flavonoid derivatives on bovine lens aldose reductase and rabbit platelet aggregation. *Chem Pharm Bull* **43**, 1385-1387.
- Pan R, Gao XH, Li Y, Xia YF, and Dai Y (2010) Anti-arthritis effect of scopoletin, a coumarin compound occurring in *Erycibe abtusifolia* Benth stem, is associated with decreased angiogenesis in synovium. *Fundam Clin Pharmacol* **24**, 477-490.
- Ryu KS and Yook CS (1967) Studies on the coumarins of the roots of *Angelica gigas* Nakai. *Yakhak Hoeji* **11**, 22-26.
- Ryu KS, Hong ND, Kim NJ, and Kong YY (1990) Studies on the coumarin constituents of the roots of *Angelica gigas* Nakai. *Kor J Pharmacogn* **21**, 64-68.
- Santiago JV (1993) Lessons from the diabetes control and complications trial. *Diabetes* **42**, 1549-1554.
- Sasaki H, Taguchi H, Endo T, and Yosioka I (1982) The constituents of *Ledebouriella seseloides* WOLFF. I. Structures of three new chromones. *Chem Pharm Bull* **30**, 3555-3562.
- Satyajit DS, Armstrong AJ, and Waterman PG (1995) An alkaloid, coumarins and a triterpene from *Boronia algida*. *Phytochemistry* **39**, 801-804.
- Shimizu M, Ito T, Terashima S, Hayashi T, Arisawa M, Morita N, Kurokawa S, Ito K, and Hashimoto Y (1984) Inhibition of lens aldose reductase by flavonoids. *Phytochemistry* **23**(9), 1885-1888.
- Shin E, Choi KM, Yoo HS, Lee CK, Hwang BY, and Lee MK (2010) Inhibitory effects of coumarins from the stem barks of *Fraxinus rhychophylla* on adipocyte differentiation in 3T3-L1 cells. *Biol Pharm Bull* **33**, 1610-1614.
- Ueda H, Kuroiwa E, Tachibana Y, Kawanishi K, Ayala F, and Moriyasu M (2004) Aldose reductase inhibitors from the

- leaves of *Myrciaria dubia* (H. B. & K.) McVaugh. *Phytomedicine* **11**, 652-656.
- Wei Y and Ito Y (2006) Preparative isolation of imperatorin, oxypeucedanin and isoimperatorin from traditional Chinese herb "bai zhi" *Angelica dahurica* (Fisch. Ex Hoffm) Benth. et Hook using multidimensional high-speed counter-current chromatography. *J Chromatogr A* **1115**, 112-117.
- Xiao H and Parkin K (2006) Isolation and identification of Phase II enzyme-inducing agents from nonpolar extracts of green onion (*Alliums* pp.). *J Agric Food Chem* **54**, 8417-8424.
- Yabe-Nishimura C (1998) Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. *Pharmacol Rev* **50**, 21-33.